Skip to content
Catalyst

N-hexadecanoylethanolamineFinding

N-hexadecanoylethanolamine decreases intraocular pressure

lowersVery limited evidenceFinding

01 · The sentence it was drawn from

“Three-month PEA intake reduced IOP and led to significantly improved FMD values in OH patients compared to placebo, by ameliorating peripheral endothelial function, and its positive effect lasted longer than the period of PEA consumption.”
Quoted verbatim from Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study.
This finding among the 2 findings on its endpoint

N-hexadecanoylethanolamine

Intraocular pressure

lowers

Who
Never-treated ocular hypertensive patients; randomized, double-blind, placebo-controlled crossover with two-month washout
Dose studied
PEA 300 mg twice a day for three months

Very limited evidencePMID 23307959 · 2013

02 · The study

Study
crossover
Duration
3 months

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

03 · The paper

Investigative ophthalmology & visual science
What else it reported2 findings · 1 compound · 2 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M70GXPZDPA61BPAWXJTQSHFS